Natco Pharma launches generic hepatitis C drug in India
The company has launched a generic version of sofosbuvir 400 mg/velpatasvir 100 mg fixed dose combination in India under the brand name ‘Velpanat’, Natco Pharma said in a BSE filing today.
The company’s product is a generic version of Gilead Sciences Inc’s Epclusa tablets.
Epclusa is used to treat adults with chronic hepatitis C genotype 1 to 6 with or without cirrhosis, Natco Pharma said.
Natco Pharma has priced its generic tablets at an MRP of Rs. 18,500 for a bottle of 28 tablets in India, the company said.
The company “has signed a non-exclusive licensing agreement with Gilead Sciences Inc to manufacture and sell generic versions of its chronic hepatitis C medicines in 101 developing countries, it added.
Shares of Natco Pharma were trading up by 0.63 per cent at Rs. 907.25 on the BSE.